Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$10.51M, compared with -$2.75M a year earlier.
Context
- Net debt amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -282.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 6.74M USD
- Year-over-year change
- +264.7%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.74M | +264.7% |
| FY2024 | 2024-12-31 | (4.09M) | +41.5% |
| FY2023 | 2023-12-31 | (6.99M) | +48.1% |
| FY2022 | 2022-12-31 | (13.47M) | +50.5% |
| FY2021 | 2021-12-31 | (27.2M) | — |
Net Debt vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -282.0% is the 8th highest of 9, against a peer median of +6.9%.
- Net debt amounts to 100.0% of total assets for GLSI, versus a peer median of 71.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $269.47M USD | +266.3% | — | 144.5% | |
| Mar 2026 | -CA$4.99M CAD | +65.1% | — | 61.1% | |
| Mar 2026 | -$5.84M USD | +3.5% | — | 19.7% | |
| Mar 2026 | -$10.51M USD | -282.0% | — | 100.0% | |
| Mar 2026 | -$24.29M USD | +10.2% | — | 8.9% | |
| Mar 2026 | -$30.67M USD | -94.2% | — | 84.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | -$34.03M USD | +18.6% | — | 50.9% |
| Mar 2026 | -$78.21M USD | -426.3% | — | 81.6% | |
| Mar 2026 | -$100.13M USD | -6.9% | — | 83.0% | |
| Peer median (excluding GLSI) | — | +6.9% | — | 71.4% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.